kentucky semaglutide law firm glp-1 digestive blockage lawyer kentucky semaglutide digestive blockage law firm semaglutide digestive blockage legal team in kentucky Semaglutide Claim Eligibility for Injured Consumers-150cent kentucky semaglutide gi semaglutide bowel obstruction law firm

The phase III REDEFINE 1 study results, released in December 2024, showed that the CagriSema treatment group lost 22.7% of their weight after 68 weeks, significantly outperforming the single-target control drugs (semaglutide group lost 16.1%, cagrilintide group lost 11.8%)

In aggregate, recent studies further support the association between elevated GGT activity and the risk of incident T2D and lay the foundations for monitoring and lowering GGT levels as a reasonable public health target for T2D prevention

Most patients begin to see noticeable weight loss within 46 weeks of consistent use

These rates appear to be higher than those reported in clinical trials, for example, 22.6% of patients prematurely discontinued therapy during the 24-month trial period in the SUSTAIN 6 trial of semaglutide [37], and 27.6% of randomised patients prematurely discontinued albiglutide during the 25-month trial period in the HARMONY trial [86]